David Hollar
Lymphoma represents a myriad collection of neoplasms that impact lymphocytes. This cancer often involves disrupted cytokine, immune surveillance, and gene regulatory signaling, sometimes with expression of Epstein Barr Virus (EBV). We explored mutation patterns for People experiencing Lymphoma (PeL) in the National Cancer Institute (NCI) Genomic Data Commons (GDC), which contains detailed, deidentified genomic data on 86,046 people who have/had cancer with 2,730,388 distinctive mutations in 21,773 genes. The database included information on 536 (PeL), with the primary focal sample being the n = 30 who had complete mutational genomic data...
March 4, 2023: Current Problems in Cancer
Moustafa A Mansour, Dyana F Khalil, Ahmad A Ayad
No abstract text is available yet for this article.
February 17, 2023: Current Problems in Cancer
Vanessa E Kennedy, Kelsey Natsuhara, Nina D Shah, Shagun Arora, Jeffrey Wolf, Thomas G Martin, Mandar A Aras, Alfred Chung, Sandy W Wong
Light chain amyloidosis (AL) is a plasma cell dyscrasia characterized by organ dysfunction, morbidity, and early mortality. Daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone is now standard frontline AL therapy; however, not all patients are candidates for this intensive regimen. Given the potency of Daratumumab, we evaluated an alternative frontline regimen: daratumumab, bortezomib, and limited-duration dexamethasone (Dara-Vd). Over a 3 year period, we treated 21 patients with Dara-Vd...
February 14, 2023: Current Problems in Cancer
Giorgio Bogani, Robert L Coleman, Ignace Vergote, Francesco Raspagliesi, Domenica Lorusso, Bradley J Monk
Tisotumab vedotin (TV) is an antibody-drug conjugate used for the treatment of adult patients with recurrent or metastatic cervical cancer. TV comprised of a monoclonal antibody against tissue factor and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. The innovaTV-201 and innovaTV-204/GO30xx/ENGOT-cx6 trials showed that TV has clinically meaningful and durable antitumor activity in pretreated patients with recurrent or metastatic cervical cancer. The innovaTV-204 trial showed that TV monotherapy resulted in an objective response rate of 24% (including 7% and 17% complete and partial responses, respectively)...
February 10, 2023: Current Problems in Cancer
Marco De Felice, Giacinto Turitto, Carola Borrelli, Carmine Menditto, Rodolfo Cangiano
Non-Small Cell Lung Cancer (NSCLC) with bone metastasis and poor performance status has the worst prognosis even in strong PD-L1 expression patients. Treatment approach includes immuno- or chemo-immunotherapy, Radiotherapy (RT) and Bone-Targeted Therapy (BTT) but there is insufficient data to suggest the best time to use each of them, alone or in combination. Using an integrated and synergistic treatment strategy with immunotherapy, radiotherapy, and Denosumab as BTT is probably the best treatment planning for metastatic NSCLC for both good and poor performance status patients, although more data are needed to confirm this approach...
January 15, 2023: Current Problems in Cancer
Varsha Huddar, Smita Vernekar, Natasha Tatpati, Shamli Thali, Pamela V D'Silva
BACKGROUND AND PURPOSE: Anxiety and fatigue is a common symptom that is seen in cancer survivors, who have recently been diagnosed as well as those who are undergoing chemotherapy and radiation therapy as they are emotionally distressed. Progressive relaxation technique and Benson's relaxation is seen to be efficacious in lowering anxiety and fatigue in cancer survivors as individual treatment. To compare the depiction of progressive relaxation technique and Benson's technique on anxiety using Hamilton anxiety scale (HAM-A), blood pressure (BP) and heart rate (HR), and fatigue using cancer fatigue scale (CFS)...
December 16, 2022: Current Problems in Cancer
Yong-Chao Dang, Qing-Tao Kong, Zhen Wang, Hong Sang
AIM: This is a prospective study of cutaneous adverse events (CAEs) in lung cancer patients treated by programmed cell death-1(PD-1) inhibitors and programmed cell death-ligand 1(PD-L1) inhibitors-based single or combination therapy. PATIENTS & METHODS: It were included that lung cancer patients who developed CAEs from January 2019 to July 2021 after applying PD-1/PD-L1 inhibitors in our institution. RESULTS: A total of 107 patients with 112 CAEs were enrolled, of which 71 patients received PD-1/PD-L1 inhibitors plus chemotherapy, 31 patients received PD-1/PD-L1 inhibitors plus anti-angiogenic/targeted therapy, and 5 patients received PD-1/PD-L1 inhibitors monotherapy...
December 15, 2022: Current Problems in Cancer
Lalit Kumar, Avinash Upadhyay, Aarthi S Jayaraj
Management of locally advanced cervix cancer underwent major change 2 decades back when concurrent chemotherapy (CCRT) (with cisplatin alone or in combination) along with definite radiation therapy (external + brachytherapy) was found to be superior compared to radiation alone in a series of randomized trials. Since then CCRT has been the standard treatment approach; this has resulted in 5-year overall survival rate of 66% and disease-free survival (DFS) of 58%. About 30% to 40% of patients with locally advanced cervical cancer continue to have treatment failure...
December 2022: Current Problems in Cancer
Aarthi S Jayraj, Sunesh Kumar, Neerja Bhatla, Prabhat Singh Malik, Sandeep Mathur, Krithika Rangarajan, Perumal Vanamail, Sanjay Thulkar, Lalit Kumar
Management of central nervous system (CNS) metastases from epithelial ovarian cancer (EOC) is an unmet need. We analyzed data on 41 such patients to evaluate predictors of outcome. Between January, 2010 and December 2020, among 1028 patients with EOC treated at our institute 41 (3.98%) developed CNS metastasis. Median age of patients was 48 years, ranging from 22 to 75 years. Primary outcome measure was progression free survival (PFS). Overall survival (OS), and analysis of prognostic factors were secondary outcome measures...
November 30, 2022: Current Problems in Cancer
Olivia Young, Nealie Ngo, Leslie Lin, Laura Stanbery, Justin Fortune Creeden, Danae Hamouda, John Nemunaitis
Folate is a B vitamin necessary for basic biological functions, including rapid cell turnover occurring in cancer cell proliferation. Though the role of folate as a causative versus protective agent in carcinogenesis is debated, several studies have indicated that the folate receptor (FR), notably subtype folate receptor alpha (FRα), could be a viable biomarker for diagnosis, progression, and prognosis. Several cancers, including gastrointestinal, gynecological, breast, lung, and squamous cell head and neck cancers overexpress FR and are currently under investigation to correlate receptor status to disease state...
November 17, 2022: Current Problems in Cancer
David Garrido, Irma Slavutsky, Eloisa Riva
Cytogenetic abnormalities (CA) such as t(4;14), t(14;16), and del(17p), are associated with a poor prognosis in Multiple Myeloma (MM) patients. However, there is scarce information regarding the Latin-American population. This study aims to analyze the impact of t(4;14), t(14;16), and del(17p) on the progression-free survival (PFS) and overall survival (OS) of transplant-eligible newly-diagnosed MM (NDMM) patients in Latin America. Retrospective survival analysis based on the Grupo de Estudio Latinoamericano de MM (GELAMM) registry, including all adult patients with NDMM harboring CA t(4;14), t(14;16), and/or del(17p)...
November 17, 2022: Current Problems in Cancer
Haoqi Wang, Yuyang Lu, Yilun Li, Sainan Li, Xi Zhang, Cuizhi Geng
To construct a nomogram for early prediction of pathological complete response (pCR) in patients with breast cancer (BC) after neoadjuvant chemotherapy (NAC). A total of 257 patients with BC from the fourth hospital of Hebei Medical University were included in the study. The patients were divided into training (n = 128) and validation groups (n = 129). Variables were screened using univariate and multivariate logistic regression analyses, and the nomogram model was set up based on the training group...
November 1, 2022: Current Problems in Cancer
Selin Küçükyurt, Kübra Şahin, Umut Yılmaz, Abdülkadir Erçalışkan, Tuba Özkan Tekin, Damla Ortaboz, Tuğrul Elverdi, Ayşe Salihoğlu, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Ahmet Emre Eşkazan
The coronavirus disease 2019 (COVID-19) pandemic has brought life to a standstill globally. Intermittent quarantines were applied to control the pandemic and reduce contamination. During the pandemic, patients with hematological malignancies were among the most vulnerable population. Our aim was to compare in terms of demographic data, disease-related factors, symptom-to-diagnosis interval, diagnosis-to-treatment interval , and interim and end-of-treatment response in classical Hodgkin lymphoma patients diagnosed during the pandemic and in the pre-pandemic periods...
October 12, 2022: Current Problems in Cancer
Yuxin Liu, Liu Shi, Kai Chen, Weijun Ye
Unlike cervical squamous cell carcinoma (CSCC), no uniform standard has been implemented to identify serum biomarkers for adenocarcinoma of the cervix (ADC). In the present study, we aimed to determine whether pretreatment serum tumor markers were of prognostic value in patients with ADC and constructed and validated the novel accurate nomogram for stratifying the risk groups. Patients with ADC who underwent curative hysterectomy or definitive radiotherapy from January 2011 to December 2016 were included. Significant factors independently predicting prognosis were selected by univariate multivariate Cox proportional hazard regression models and adopted for constructing the overall survival (OS) and progression-free survival (PFS) prediction nomograms...
October 9, 2022: Current Problems in Cancer
Palma Fedele, Valeria Sanna, Anna Natalizia Santoro, Maria Laura Iaia, Alessandro Fancellu
Precision medicine advances are opening new opportunities in the treatment of Her2 driven cancers. Her2 signaling activation was found in around 20% of breast cancers about 3 decades ago and define an aggressive subtype of the disease. Nowadays antiHer2 targeted approach is standard of care in both metastatic and early-stage Her2 -positive breast cancer and has changed the general course of the disease. However, the challenge of personalizing cancer treatments through de-escalation and escalation strategies is still open, especially in the early setting of the disease...
October 2022: Current Problems in Cancer
Vikas Garg, Aarthi S Jayaraj, Lalit Kumar
Endometrial cancer (EC) is common malignancy in women and its incidence is slowly on the rise. Accurate surgical staging, with aggressive cytoreduction when indicated, remains the most critical step in the treatment. Careful pathological evaluation and/or molecular risk stratification guides for proper systemic adjuvant radiotherapy ± chemotherapy. Recurrent and metastatic EC has dismal prognosis and palliative therapies (chemotherapy, hormonal therapy or radiation) forms the backbone of treatment. There is an unmet need of newer therapies to improve survival in such cases...
October 2022: Current Problems in Cancer
Sara E Beltrán Ponce, Charles R Thomas, Dayssy A Diaz
Disparities in cancer care and outcomes between racial and ethnic groups, urban and rural populations, and socioeconomic classes are well documented and represent one of the greatest forms of injustice throughout the United States. Despite the development of increasingly efficacious treatments, survival disparities have widened over time, with known impacts based on both medical factors and social determinants of health including education, neighborhood, factors, and access to care, among others. In this review, we discuss current state of inequities in access to cancer services, treatment-related financial toxicity, and disparities within the oncology workforce, all of which significantly impact the ability of clinicians to provide high quality, equitable, and guideline-compliant care for all people with cancer...
October 2022: Current Problems in Cancer
Filippo Pesapane, Giorgio Maria Agazzi, Anna Rotili, Federica Ferrari, Andrea Cardillo, Silvia Penco, Valeria Dominelli, Oriana D'Ecclesiis, Silvano Vignati, Sara Raimondi, Anna Bozzini, Maria Pizzamiglio, Giuseppe Petralia, Luca Nicosia, Enrico Cassano
We performed a systematic review and a meta-analysis of studies using MRI-radiomics for predicting the pathological complete response in breast cancer patients undergoing neoadjuvant therapy , and we evaluated their methodological quality using the radiomics-quality-score (RQS). Random effects meta-analysis was performed pooling area under the receiver operating characteristics curves. Publication-bias was assessed using the Egger's test and visually inspecting the funnel plot. Forty-three studies were included in the qualitative review and 34 in the meta-analysis...
October 2022: Current Problems in Cancer
Caroline Hesko, Nupur Mittal, Viswatej Avutu, Stefanie-M Thomas, Jessica-L Heath, Michael-E Roth
Adolescent and young adult (AYA) participation in cancer clinical trials (CCTs) is suboptimal, hindering further improvements in survival, quality of life, and basic understanding of cancer pathophysiology in this population. Prior studies have identified barriers and facilitators to AYA CCT enrollment; however, few interventional studies have attempted to address these barriers and measure tangible changes. In September 2020, a task force was established to address CCT enrollment barriers at a multi-institutional level utilizing a quality improvement collaborative model for improvement...
September 28, 2022: Current Problems in Cancer
Wenkai Zhou, Xu Zhang, Yisheng Feng, Yu Zhang, Zheqi Liu
Head and neck squamous cell carcinoma (HNSCC) is considered an immunosuppressive malignancy. Cross-talk between cancer cells and immune cells is modulated in part by CC ligand (CCL) chemokines, having a major effect on tumor progression. However, the predictive value and function of CCL family members in HNSCC have not been elucidated. Here, the predictive value of CCL members in cancer prognosis and Immune checkpoint blockade therapy response was investigated. CCL17 and CCL22 were screened as the key CCL chemokines in HNSCC through co-expression analysis...
September 21, 2022: Current Problems in Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.